Shots:

• The P-II ZUMA-5 study involves assessing Yescarta (axicabtagene ciloleucel) in patients with r/r iNHL after at least 2L of systemic therapy. After a single infusion of Yescarta- 92% of patients responded- including 76% of patients achieving a CR @median follow-up of 17.5 mos.- results presented at ASH
• The data supports the US FDA’s acceptance of BLA and is currently under PR for r/r FL- MZL- after two or more prior lines of systemic therapy- with an anticipated PDUFA date as Mar 5- 2021
• Yescarta is the first CAR T-cell therapy to be approved by the US FDA for patients with r/r large B-cell lymphoma after two or more lines of systemic therapy

 ­ Ref: Businesswire | Image: Seek Vector Logo